For patients with symptomatic condition requiring therapy, ibrutinib is commonly recommended based upon 4 section III randomized clinical trials evaluating ibrutinib with chlorambucil monotherapy106 and also other frequently employed CIT mixtures, particularly FCR, bendamustine in addition rituximab and chlorambucil in addition obinutuzumab (ClbO).